JAAD onlineEccrine squamous syringometaplasia associated with dabrafenib therapy
References (5)
- et al.
Chemotherapy-related bilateral dermatitis associated with eccrine squamous syringometaplasia: reappraisal of epidemiological, clinical, and pathological features
J Am Acad Dermatol
(2011) - et al.
Cutaneous toxicities of RAF inhibitors
Lancet Oncol
(2013)
There are more references available in the full text version of this article.
Cited by (9)
Encorafenib-induced eccrine squamous syringometaplasia
2024, Annales de Dermatologie et de VenereologieAdverse cutaneous reactions to chemotherapeutic drugs
2020, Clinics in DermatologyCutaneous Adverse Reactions of Anticancer Agents
2019, Dermatologic ClinicsCitation Excerpt :NEH due to BRAFi does not seem to recur on switching to an alternative BRAFi, and this can be used to manage NEH without compromising the chemotherapy regimen.21 Eccrine squamous syringometaplasia (ESS) is an uncommon cutaneous eruption characterized by erythematous macules, papules, and plaques that appear about 2 to 30 days after starting chemotherapy.24,25 A case series observed the bilaterally symmetric intertriginous pattern to be the most common presentation.
Sorafenib-induced eccrine squamous syringometaplasia
2022, Australasian Journal of DermatologyNeutrophilic eccrine hidradenitis can be induced by BRAF inhibitors
2017, British Journal of Dermatology
Funding sources: None.
Conflicts of interest: None declared.
Copyright © 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.